← Eichor
Condition: Esophageal Squamous Cell Carcinoma Escc Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Esophageal Squamous Cell Carcinoma Escc

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Adebrelimab ±Induction Chemotherapy Followed by Concurrent Chemoradiotherapy for Unresectable Locally Advanced ESCC
Phase 2 · 1 location(s) · Fujian Medical University Union Hospital · NCT06510660PD-1 Inhibitors Combined With Local Therapy at Different Timings in Oligometastatic ESCC
Phase N/A · 1 location(s) · Fudan University · NCT07697859Consolidation of Toripalimab and Capecitabine After Chemoradiotherapy in ESCC
Phase 3 · 1 location(s) · Sun Yat-sen University · NCT07177794Induction Chemo-Immunotherapy + Radiotherapy vs Concurrent Chemoradiotherapy for Unresectable Locally Advanced Esophagea
Phase 2 · 1 location(s) · Second Affiliated Hospital of Zunyi Medical University · NCT07559045A Randomized Controlled Trial Evaluating of Prophylactic Irradiation in CRT for cT1bN0M0 ESCC
Phase 3 · 1 location(s) · National Cancer Center, Japan · NCT04328948Watch and Wait for NeoAdjuvant Concurrent Radiochemotherapy Combined With Camrelizumab in Patients With Resectable ESCC
Phase 2 · 3 location(s) · Zhejiang Cancer Hospital · NCT05507411A Phase II Clinical Study to Evaluate HLX43 in Patients With Recurrent/Metastatic ESCC Failed or Intolerance to Standard
Phase 2 · 1 location(s) · Shanghai Henlius Biotech · NCT06769113Combination Immunotherapy of Adebrelimab With Apatinib and Tegafur, Gimeracil and Oteracil Potassium Capsules for Immune
Phase 2 · 1 location(s) · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · NCT06339619A Study of Perioperative Camrelizumab Combined With Chemotherapy in Patients With Resectable ESCC
Phase 2 · 1 location(s) · The First Affiliated Hospital of Zhengzhou University · NCT05182944A Phase Ib/II Study of an Anti-HER3 Antibody, HMBD-001, With Cetuximab +/- Docetaxel in Advanced Squamous Cell Cancers
Phase 1/Phase 2 · 20 location(s) · Hummingbird Bioscience · NCT05910827DCRT vs. Surgery in Resectable ESCC Patient Achiving cCR/PR After nCI
Phase 2 · 1 location(s) · Tianjin Medical University Cancer Institute and Hospital · NCT07162506Neoadjuvant Immunotherapy Combined With Chemotherapy Sequenced With Endoscopic Resection for Esophageal Cancer (Endosurg
Phase 1 · 1 location(s) · Shanghai Zhongshan Hospital · NCT07317609Perioperative Cadonilimab Combined With Neoadjuvant Chemotherapy in Resectable Esophageal Squamous Cell Carcinoma (ESCC)
Phase 2 · 1 location(s) · Akeso · NCT07263919A Study Evaluating the Safety and Efficacy of JS212 Combination Therapy in Patients With Advanced Esophageal Squamous Ce
Phase 2 · 1 location(s) · Shanghai Junshi Bioscience Co., Ltd. · NCT07484724A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors
Phase 1 · 9 location(s) · Normunity AccelCo, Inc. · NCT07182149QLC5508 vs. Chemotherapy in Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma
Phase 3 · 1 location(s) · Qilu Pharmaceutical Co., Ltd. · NCT07463573A Noninvasive and Screening miRNA Signature for Gastrointestinal Cancer
Phase N/A · 1 location(s) · City of Hope Medical Center · NCT07224750A Phase II Clinical Study of Sintilimab Combined with Chemotherapy Followed by Concurrent Chemoradiotherapy for Locally
Phase 2 · 1 location(s) · Shanghai Chest Hospital · NCT06709417Intestinal Low-Dose Radiotherapy Plus Immunochemotherapy for Conversion of Borderline Resectable/Unresectable Esophageal
Phase 2 · 1 location(s) · Chuangzhen Chen · NCT07339488Adebrelimab Neoadjuvant Treatment for Resectable ESCC: 2 vs 4 Cycles Study
Phase 2 · 1 location(s) · Tang-Du Hospital · NCT06663059A Study of IO Plus Radiotherapy in Patients With Advanced ESCC.
NA · 1 location(s) · Fudan University · NCT05760391Hypofractionated vs. Conventional Chemoradiotherapy After Induction Chemo-immunotherapy for Unresectable Esophageal Squa
Phase 2 · 1 location(s) · Sun Yat-sen University · NCT06912074Efficacy and Safety of Tislelizumab Plus Chemotherapy as Conversion Therapy in Unresectable Locally Advanced ESCC
Phase N/A · 1 location(s) · Shandong Provincial Hospital · NCT07549100An Observational Study on the Safety and Efficacy of Immunotherapy Combined With Concurrent Chemoradiotherapy in Elderly
Phase N/A · 1 location(s) · Three Gorges Hospital of Chongqing University · NCT07080437Tislelizumab Plus Concurrent Chemoradiation in Older With ESCC
Phase 2 · 1 location(s) · Tianjin Medical University Cancer Institute and Hospital · NCT06061146Comparison of Chemoradiotherapy and Chemoradiotherapy Combined With Consolidation Chemotherapy for ESCC
NA · 1 location(s) · The First Affiliated Hospital with Nanjing Medical Universit · NCT05775419A Study of Sigvotatug Vedotin in Advanced Solid Tumors
Phase 1 · 158 location(s) · Seagen, a wholly owned subsidiary of Pfizer · NCT04389632Optimization of Treatment Strategy for Unresectable cN3 Esophageal Squamous Cell Carcinoma
Phase 2 · 1 location(s) · Ruijin Hospital · NCT06122493MR-Guided Radiotherapy Dose Escalation Trial for Esophageal Squamous Cell Carcinoma
Phase 1 · 1 location(s) · UMC Utrecht · NCT07359417Individualized Tumor-Informed CtDNA Analysis for Monitoring Postoperative Recurrence in ESCC (NEOCRTEC2401)
Phase N/A · 1 location(s) · Sun Yat-Sen University Cancer Center · NCT06561178
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.